Morgan Stanley Sticks to Its Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692)Tip Ranks·13 hours ago03692-0.49%
Key facts: GSK Q2 revenue up 5%, £1.9B savings target; ris-rez PFS metTradingView·2 days ago, 02:15 AMGSK-1.02%03692-0.49%
GSK’s partner posts positive osteosarcoma data for B7-H3 drug, bolstering oncology pushTip Ranks·Jul 28 at 05:12 AMGSK-1.02%03692-0.49%
REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-RezLondon Stock Exchange·Jul 28 at 05:06 AMGSK-1.02%03692-0.49%
Hansoh Pharma says Artemis-011 Phase 3 trial of HS-20093 meets primary PFS endpoint in osteosarcomaPUBT·Jul 28 at 05:01 AM03692-0.49%
Nomura Expects HANSOH PHARMA Interim Profit Dragged by R&D Expenses; Cuts TP to HKD37.24AASTOCKS News·Jul 27 at 01:52 AM03692-0.49%
CLSA Raises HANSOH PHARMA TP to HKD42, Expects Multiple New Drug Launches Next Yr to Support Earnings GrowthAASTOCKS News·Jul 26 at 10:14 PM03692-0.49%
Hong Kong Mid-Caps Drive Summer Dealmaking Amid USD 2.3 Billion Bio-Licensing and Stock BuybacksGlobal Report·Jul 22 at 04:18 AM03692-0.49%01187-2.29%
Hansoh Pharmaceutical Group Company Limited (3692) Gets a Buy from Morgan StanleyTip Ranks·Jul 15 at 08:55 PM03692-0.49%
Hansoh-backed Avere agrees to merge with NextCure in all-stock dealPUBT·Jul 14 at 05:01 AM03692-0.49%NXTC-0.20%
